Amgen beats expectations in 2014 and gears up for more growth
This article was originally published in Scrip
Executive Summary
Amgen, the world's biggest biotech company, reported better-than-expected full year and fourth quarter 2014 financial results on 27 January. Revenues for 2014 increased 7% to $20.1bn while EPS increased 14% to $8.70. Estimates had put full-year revenue at $19.94bn and EPS at $8.59 (scripintelligence.com, 23 January 2015).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.